Advertisement Glatopa(R) (glatiramer acetate injection) logo
IT’S TIME TO GO GLATOPA:
Robust Patient Support Helps Ensure Seamless Starts and Transitions
COPAXONE GLATOPA
Glatopa, the first FDA-approved, fully substitutable generic glatiramer acetate (GA), is now available in a 40 mg/mL, 3-times-a-week dosage strength.1-3 Sandoz now offers the complete GA portfolio.
In addition to therapeutic equivalence,3 Glatopa offers many of the support services expected with a brand name. Patients taking Glatopa are backed by GlatopaCare®, which provides free, individualized patient services.
Surveys indicate satisfaction with GlatopaCare
GlatopaCare helps to ensure patients feel confident using Glatopa, whether they’re new to GA or making a switch. Analyses demonstrate Glatopa and GlatopaCare provide satisfaction for physicians and patients, respectively:
97% of Glatopa patients are satisfied with GlatopaCare4*
97% of Glatopa patients are compliant with their Glatopa regimen,
similar to Copaxone compliance rates
93% of neurologists who use Glatopa are satisfied
HCP, healthcare professional.
*Based on a survey conducted Aug 16-25, 2016, of 151 patients taking Glatopa 20 mg/mL and enrolled in GlatopaCare, using a scale where 1 = not at all satisfied and 7 = extremely satisfied; 146 patients, or 97%, provided a score of ≥3.
Based on a high-touch, specialty pharmacy clinical analysis of 492 Glatopa 20 mg/mL patients, 525 Copaxone® 20 mg/mL patients, and 1101 Copaxone® 40 mg/mL patients from July 2015 to Oct 2016. Compliance defined as ≥80% Medication Possession Ratio (MPR).
Independent market research. Neurologists were moderately or extremely satisfied with Glatopa based on a 1-10 scale where 1 = not at all satisfied and 10 = extremely satisfied, with moderately satisfied scored as 4-7 and extremely satisfied scored as 8-10. Scores were gathered in an online survey of 44 respondents, July-Sept 2016.
GlatopaCare provides the support that patients deserve
Glatopa Co-Pay Program
Glatopa Co-Pay Program
Eligible§ patients enrolled in GlatopaCare may have a $0 Co-Pay for their Glatopa prescriptions
Individualized Injection Support
Individualized Injection Support
Nurse Trainers provide 1-on-1 injection training in patients’ homes or by phone
24/7 Patient Support
24/7 Patient Support
Nurses are available day or night to answer questions about Glatopa and provide guidance about self-injection
Insurance and Benefits Information
Insurance and Benefits Information
GlatopaCare Representatives help patients understand their insurance benefits
Sandoz: A trusted name in generics
Glatopa is manufactured in the USA, meets rigorous FDA standards, and is backed by the trusted experience of Sandoz, a Novartis Division, known for high-quality generics.2,3
To find out more about Glatopa, contact your Sandoz Account Manager or visit glatopa.com.
Indication
Glatopa® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing-forms of multiple sclerosis.

Important Safety Information
Glatopa® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of glatiramer acetate injection 20mg/mL patients vs. 4% of those on placebo, and approximately 2% of glatiramer acetate injection 40mg/mL patients vs. none on placebo experienced a constellation of symptoms that may occur within minutes after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of glatiramer acetate injection 20mg/mL patients vs. 6% of placebo patients, and approximately 2% of glatiramer acetate injection 40mg/mL patients vs. 1% on placebo. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain was transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Because glatiramer acetate can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer acetate may interfere with recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that glatiramer acetate does this, but there has not been a systematic evaluation of this risk.

The most common adverse reactions with glatiramer acetate injection 20mg/mL vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common adverse reactions with glatiramer acetate injection 40mg/mL vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of glatiramer acetate injection. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with glatiramer acetate than placebo.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Glatopa.
The Glatopa Co-Pay Program provides up to $9,000 in annual Co-Pay support for Glatopa prescriptions. This program is not health insurance. This program is for insured patients only; uninsured cash-paying patients are not eligible. Patients are not eligible if prescriptions are paid, in whole or in part, by any state or federally funded programs, including but not limited to Medicare (including Part D, even in the coverage gap) or Medicaid, Medigap, VA, DOD, or TriCare, or private indemnity, or HMO insurance plans that reimburse you for the entire cost of your prescription drugs, or where prohibited by law. Card may not be combined with any other rebate, coupon, or offer. Card has no cash value. Sandoz reserves the right to rescind, revoke, or amend this offer without further notice.
References: 1. Glatopa [prescribing information]. Princeton, NJ: Sandoz Inc.; 2018. 2. FDA approves first generic Copaxone to treat multiple sclerosis [press release]. US Food and Drug Administration; April 16, 2015. https://wayback.archive-it.org/7993/20171102214315/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm443143.htm. Accessed June 19, 2018. 3. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration website. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM071436.pdf. Accessed June 19, 2018. 4. Data on File. Rx Crossroads GlatopaCare Survey. Sandoz Inc. Princeton, NJ. August 2016. 5. Data on File. Specialty Pharmacy Clinical Analysis. Sandoz Inc. Princeton, NJ. October 2016. 6. Data on File. MS market research report. Sandoz Inc. Princeton, NJ. September 2016.


SANDOZ A NOVARTIS DIVISION
Glatopa and GlatopaCare are registered trademarks of Novartis AG.
©2018 Sandoz Inc., a Novartis Division, 100 College Road West, Princeton, NJ 08540.
All Rights Reserved.
S-GLA-1360828 06/2018
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
×

Sign In

Not a member? Sign up now!